About US
Contact us
-
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysisAstraZeneca’s Fasenra has been stealing share from GlaxoSmithKline’s Nucala in severe asthma, and competition is even fiercer with Sanofi’s Dupixent approval. Now, AZ has released an analysis of se2019/5/20
-
NICE grants Celgene long-awaited thumbs-up for Revlimid in untreated myelomaThe old adage “better late than never” may be overused, but forCelgene, it certainly applies to England’s cost watchdogs and their stance toward the company's multiple myeloma flagship drug Revlimid.2019/5/20
-
Celgene’s Pomalyst secures breakthrough designationThe US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Celgene’s Pomalyst (pomalidomide) in HIV-positive and HIV-negative Kaposi sarcoma. Pomalyst is an oral, small2019/5/17
-
Biogen’s SMA drug Spinraza to be available on NHSThe UK’s National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness a2019/5/17
-
Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV medsGilead Sciences has faced years of allegations that it sidelinedits safer, next-gen HIV drugs to reap as much revenue as possible from the older generation before the new meds hit.And a federal jud2019/5/16
-
Watch out, Dupixent. Pfizer's new JAK inhibitor could come after your eczema marketPfizer’s FDA-approved JAK inhibitor Xeljanz is currently struggling with cardiovascular safety concerns. But another candidate in the family for which Pfizer has blockbuster hopes just slew a phase 32019/5/16
-
Pfizer, Merck KGaA's latest Bavencio nod sets up 3-way kidney cancer battlePfizer and its Germany-based partner Merck KGaA finally have some good news to celebrate in their long-fought battle to broaden the market for their PD-1/PD-L1 inhibitor Bavencio: an FDA approval of2019/5/15
-
B. Braun commits $1B to expand in face of IV fluid shortagesB. Braun Medical, which has been a key figure in the nation’s shortage of IV fluids, says it is committed to helping fix the problem. It will invest $1 billion in its U.S. manufacturing and supply ch2019/5/15
-
Hey, big spender: Pharma's $6.6B TV ad outlay outranks most other industries, report saysPharma is the fourth-largest spender on TV ads in the U.S., with $6.6 billion spent over the past year. That’s according to MediaRadar’s annual study of TV ad spending, which includes OTC drug ads in2019/5/14
-
Bayer's already in the hot seat with investors. A new $2B Roundup slapdown won't helpWith angry investors at the gates and thousands of lawsuits tied up in court, Bayer’s executives have scrambled to keep their head above water. Looks like relief isn’t coming any time soon, at least2019/5/14